History Of Israeli False Flag Operations Blamed On Palestinians

[ VAT ] Recommended : ( Notes in progress - Compiled by Veterans Against Treason Founder , 100 % Disabled USAF Gulf War Veteran Thomas W. Trefts ).

Toxic Exposure Testing To Help Qualify For New VA Benefits Specific To The VA PACT ACT .

1.) Exposure Assessment Tools by Tiers and Types - Screening-Level and Refined | US EPA

Therefore Ask The SPECIFIC Following Tests : ( In Writing ✍️ ).

• The Airborne Toxicity Test - https://www.epa.gov/fera/air-toxics-risk-assessment-reference-library-volumes-1-3
•
•
•
•
•
• Detection of Mycoplasma Genus PCR Test for the PATENTED Mycoplasma Fermentans vaccine contaminate. Search Results | Pathogens and Disease | Oxford Academic https://academic.oup.com/femspd/search-results?page=1&qb={Keywords1:%22Quantitative%20PCR%20assay%22}&SearchSourceType=1
•
Detection of Mycoplasma fermentans in human saliva with a polymerase chain reaction-based assay - PubMed

https://pubmed.ncbi.nlm.nih.gov/8735018/
•
• Detection of SQUALENE ANTIBODIES stemming from exposure to the SYNTHETIC SQUALENE ADJUVANT MF-59 aka “ Motherfucker 59 “ which goes by over 50 aliases and was first introduced into the population via the Experimental Gulf War Era Anthrax Vaccine 💉 which was authorized through President Bill Clinton via Project Badger 🦡. It is now used most commonly in the guise of AS03 and AF03. Who invented this SYNTHETIC SQUALENE VACCINE 💉 ADJUVANT ? Former U.S. Army Scientist 👨‍🔬 Dr. Carl Alving - see : Crimes Against Humanity. - This test is being withheld by Autoimmune Technologies: Autoimmune Technologies LLC, New Orleans

Laboratory Tests
GULF WAR SYNDROME
 
The Patented Anti-Squalene Antibody Assay, or ASA Assay
The patented Anti-Squalene Antibody Assay, or ASA Assay, is a test that detects antibodies to squalene in human blood. Peer-reviewed research data that was obtained by using this test has linked squalene-contaminated lots of the vaccine used in the DoD's post-1997 Anthrax Vaccine Immunization Program (AVIP) to the development of anti-squalene antibodies. These antibodies were previously linked to the multi-symptom rheumatic illness known as Gulf War Syndrome. For more information about this data and its implications, see the Gulf War Syndrome Research Page.
U.S. Army researchers duplicated this test, and in November 2000 the Army researchers published their research confirming the discovery of anti-squalene antibodies. A patent on the ASA Assay was awarded in April 2001, and Autoimmune Technologies holds the rights to that patent. The patent covers various methods for detecting anti-squalene antibodies, including the testing method that was used by the Army researchers. To enable the DoD to sponsor a large confirmatory study of the link between squalene contamination in vaccines and GWS, Autoimmune has offered the patented ASA Assay technology to the Department of Defense and has strongly urged the DoD to sponsor such a study.
In addition to helping identify patients with GWS, the discovery of anti-squalene antibodies might also provide a key to more effectively treating GWS patients. The presence of the antibodies in GWS patients indicates that the immune system is involved in the development of GWS. Effective drugs which modulate the human immune system are already in wide use, but they have not been previously considered to be appropriate for GWS patients. The published data now suggests that the use of immune modulators in GWS patients should be studied.
Autoimmune Technologies is not currently offering the ASA Assay for investigation into individual GWS cases, but when the benefits of the test become clear to all of the groups involved in assessing GWS, Autoimmune will immediately make the ASA Assay available to interested physicians for investigational use.
GWS patients or physicians who would like to receive notification when the Assay does become available for investigational use may send their name, mailing address, and their physician's name if they are a patient, to GWS@autoimmune.comvia e-mail or to the postal address given in the How to Contact Us page. IMPORTANT NOTE CONCERNING E-MAIL: Because of the recent proliferation of "spam" messages, the GWS@autoimmune.com mailbox is now being filtered by subject line. Please begin the subject line of your e-mail message with the word Test in order to pass through the filter.


For more information, go to the Gulf War Syndrome Research Page
 
This material is not intended to take the place of a physician's advice.
Laboratory Tests
GULF WAR SYNDROME
The Patented Anti-Squalene Antibody Assay, or ASA Assay
The patented Anti-Squalene Antibody Assay, or ASA Assay, is a test that detects antibodies to squalene in human blood. Peer-reviewed research data that was obtained by using this test has linked squalene-contaminated lots of the vaccine used in the DoD's post-1997 Anthrax Vaccine Immunization Program (AVIP) to the development of anti-squalene antibodies. These antibodies were previously linked to the multi-symptom rheumatic illness known as Gulf War Syndrome. For more information about this data and its implications, see the Gulf War Syndrome Research Page.
U.S. Army researchers duplicated this test, and in November 2000 the Army researchers published their research confirming the discovery of anti-squalene antibodies. A patent on the ASA Assay was awarded in April 2001, and Autoimmune Technologies holds the rights to that patent. The patent covers various methods for detecting anti-squalene antibodies, including the testing method that was used by the Army researchers. To enable the DoD to sponsor a large confirmatory study of the link between squalene contamination in vaccines and GWS, Autoimmune has offered the patented ASA Assay technology to the Department of Defense and has strongly urged the DoD to sponsor such a study.
In addition to helping identify patients with GWS, the discovery of anti-squalene antibodies might also provide a key to more effectively treating GWS patients. The presence of the antibodies in GWS patients indicates that the immune system is involved in the development of GWS. Effective drugs which modulate the human immune system are already in wide use, but they have not been previously considered to be appropriate for GWS patients. The published data now suggests that the use of immune modulators in GWS patients should be studied.
Autoimmune Technologies is not currently offering the ASA Assay for investigation into individual GWS cases, but when the benefits of the test become clear to all of the groups involved in assessing GWS, Autoimmune will immediately make the ASA Assay available to interested physicians for investigational use.
GWS patients or physicians who would like to receive notification when the Assay does become available for investigational use may send their name, mailing address, and their physician's name if they are a patient, to GWS@autoimmune.comvia e-mail or to the postal address given in the How to Contact Us page. IMPORTANT NOTE CONCERNING E-MAIL: Because of the recent proliferation of "spam" messages, the GWS@autoimmune.com mailbox is now being filtered by subject line. Please begin the subject line of your e-mail message with the word Test in order to pass through the filter.


For more information, go to the Gulf War Syndrome Research Page
This material is not intended to take the place of a physician's advice.

Autoimmune Technologies, LLC
830 Union Street, Suite 200 |  New Orleans, Louisiana, 70112, USA
T: (504) 529-9944 | F: (504) 529-8982 | E: mailbox@autoimmune.com